In the case of patient #2, avapritinib, which is the preferred therapeutic option for treating GIST harboring the PDGFRA D842V mutation in Western countries, has not yet received regulatory approval in our healthcare system. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.